Molecular Partners AG (MOLN):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Molecular Partners AG (MOLN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7548
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:41
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スイス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Molecular Partners AG (Molecular Partners) is a clinical stage biopharmaceutical company that provides biological drugs. The company provides advanced pipeline products such as abicipar, a designed ankyrin repeat protein based anti-angiogenic drug developed for diabetic macular edema and wet age- macular degeneration. It develops drugs on DARPin base technology and other product candidates. Molecular Partners develops products for ophthalmic conditions, cancer, immune disorders and other indications. The company also provides clinical trial services and small protein therapies called Darpin therapeutics. It has partnership with pharmaceutical company to strengthen drug platforms through in-house development, licensing, collaboration, and others. Molecular Partners is headquartered in Zurich, Switzerland.

Molecular Partners AG (MOLN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Molecular Partners AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Molecular Partners AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Molecular Partners AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Molecular Partners AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Molecular Partners AG, Medical Devices Deals, 2012 to YTD 2018 9
Molecular Partners AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Molecular Partners AG, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Molecular Partners and AstraZeneca Enter into Partnership 11
Molecular Partners Reinforces Partnership with Allergan 12
Allergan Exercises Option Agreement with Molecular Partners 13
Equity Offering 14
Molecular Partners Raises USD31.7 Million in Private Placement of Shares 14
Molecular Partners Announces Partial Exercise of Underwriter’s Option for IPO for USD108 Million 15
Molecular Partners AG – Key Competitors 17
Molecular Partners AG – Key Employees 18
Molecular Partners AG – Locations And Subsidiaries 19
Head Office 19
Recent Developments 20
Financial Announcements 20
Aug 30, 2018: Molecular Partners reports key financials for H1 18 and corporate highlights for the second quarter 2018 20
Feb 08, 2018: Molecular Partners Reports Significant Progress of Pipeline and Preliminary Unaudited Key Financials for 2017 – Key Value Inflection Points in 2018 23
Aug 30, 2017: Molecular Partners reports key financials and corporate highlights for H1 2017: Pipeline development on track with several key milestones ahead 26
Feb 09, 2017: Molecular Partners reports preliminary unaudited key financials for 2016: Advancements across all therapeutic areas – Ongoing strong cash position 29
Corporate Communications 31
Jun 21, 2018: Molecular Partners Names Pamela A. Trail as Chief Scientific Officer; Michael T. Stumpp Assumes Role of Chief Operating Officer of the Company 31
May 12, 2017: Patrick Amstutz Appointed as Chief Executive Officer 32
May 11, 2017: Shareholders of Molecular Partners approved all Board proposals at the Annual General Meeting – Gwen Fyfe elected new Board member 33
Apr 12, 2017: Christian Zahnd appointed as Honorary Chairman of the Board of Directors as he decided not to stand for re-election as member of the Board of Directors at the Annual General Meeting 2017 34
Product News 35
11/09/2017: Molecular Partners Expands and Advances Robust Pipeline of DARPin Therapies in Oncology and Ophthalmology 35
Other Significant Developments 36
Apr 26, 2018: Further MP0250 clinical data and partner interest underline Molecular Partners’ continued progress of its proprietary oncology compounds 36
Oct 26, 2017: Molecular Partners: Interim Management Statement Q3 2017 39
Appendix 41
Methodology 41
About GlobalData 41
Contact Us 41
Disclaimer 41

List of Tables
Molecular Partners AG, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Molecular Partners AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Molecular Partners AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Molecular Partners AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Molecular Partners AG, Deals By Therapy Area, 2012 to YTD 2018 8
Molecular Partners AG, Medical Devices Deals, 2012 to YTD 2018 9
Molecular Partners AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Molecular Partners and AstraZeneca Enter into Partnership 11
Molecular Partners Reinforces Partnership with Allergan 12
Allergan Exercises Option Agreement with Molecular Partners 13
Molecular Partners Raises USD31.7 Million in Private Placement of Shares 14
Molecular Partners Announces Partial Exercise of Underwriter’s Option for IPO for USD108 Million 15
Molecular Partners AG, Key Competitors 17
Molecular Partners AG, Key Employees 18

List of Figures
Molecular Partners AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Molecular Partners AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Molecular Partners AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Molecular Partners AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Molecular Partners AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Molecular Partners AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Molecular Partners AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Molecular Partners AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Molecular Partners AG, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Molecular Partners AG (MOLN):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • BliNK Biomedical SAS:製薬・医療:M&Aディール及び事業提携情報
    Summary BliNK Biomedical SAS (BliNK Biomedical) is a drug development company that discovers and develops antibody-based therapeutics for life threatening diseases such as cancer. The company’s lead pipeline program is a monoclonal antibody that targets novel immune-oncology and immune-checkpoint ta …
  • Buck Institute for Research on Aging-製薬・医療分野:企業M&A・提携分析
    Summary Buck Institute for Research on Aging (Buck Institute) is a healthcare institute that conducts research and offers educational services. The institute concentrates on understanding the connection between aging and chronic disease. It works to understand how normal aging contributes to the dev …
  • PCCW Limited:企業の戦略・SWOT・財務情報
    PCCW Limited - Strategy, SWOT and Corporate Finance Report Summary PCCW Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Greatcell Solar Ltd (GSL):企業の財務・戦略的SWOT分析
    Greatcell Solar Ltd (GSL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Oxford Nanopore Technologies Ltd:企業の戦略的SWOT分析
    Oxford Nanopore Technologies Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • Icelandair Group:戦略・SWOT・企業財務分析
    Icelandair Group - Strategy, SWOT and Corporate Finance Report Summary Icelandair Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Taiwan Power Co Ltd:電力:M&Aディール及び事業提携情報
    Summary Taiwan Power Company Ltd (Taiwan Power) is an integrated state-owned electric utility that offers electricity generation, transmission and distribution services. The utility generates electricity through various fuel resources including thermal, coal, gas, cogeneration and renewable sources. …
  • Edisun Power Europe AG (ESUN):企業の財務・戦略的SWOT分析
    Summary Edisun Power Europe AG (Edisun Power) is a solar power producer. The company finances, develops and operates solar power plants in various European countries. It offers technical studies, legal and financial studies, custom design, installation, work monitoring, and operation and maintenance …
  • Roust Corporation:企業のM&A・事業提携・投資動向
    Roust Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Roust Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), div …
  • SVOGL Oil Gas and Energy Ltd:企業の戦略的SWOT分析
    SVOGL Oil Gas and Energy Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Orsted Salg & Service AS:企業の戦略的SWOT分析
    Orsted Salg & Service AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • The Emirates Telecommunications Group:戦略・SWOT・企業財務分析
    The Emirates Telecommunications Group - Strategy, SWOT and Corporate Finance Report Summary The Emirates Telecommunications Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • Actuant Corporation:企業のM&A・事業提携・投資動向
    Actuant Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Actuant Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), …
  • Minerva Biotechnologies Corp:製薬・医療:M&Aディール及び事業提携情報
    Summary Minerva Biotechnologies Corp (Minerva) is a cancer therapy and regenerative medicine company that develops immunotherapies and cancer drugs. The company offers antibody for T-cell immunotherapy, which is used in advanced breast and ovarian cancers; and humanized antibodies used for prostate …
  • American Municipal Power Inc:企業の戦略的SWOT分析
    American Municipal Power Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Safaricom Ltd:企業の戦略・SWOT・財務分析
    Safaricom Ltd - Strategy, SWOT and Corporate Finance Report Summary Safaricom Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • ethris GmbH-製薬・医療分野:企業M&A・提携分析
    Summary ethris GmbH (Ethris) is a biotechnology company that develops and manufactures therapeutics. The company develops therapeutics based on its proprietary platform technologies. It uses technologies including magnetovax and SNIM RNA. Ethris’ magnetovax is a platform for personalized tumor vacci …
  • McConnell Dowell Corp Ltd:企業の戦略的SWOT分析
    McConnell Dowell Corp Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • InnerWorkings Inc:企業の戦略・SWOT・財務情報
    InnerWorkings Inc - Strategy, SWOT and Corporate Finance Report Summary InnerWorkings Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • NovoCure Ltd (NVCR):企業の財務・戦略的SWOT分析
    Summary NovoCure Ltd (NovoCure) is an drug company that offers development and commercialization of novel therapies for tumor treating fields. The company’s pipeline products find application in cancer indications such as malignant melanoma, hepatocellular carcinoma, ovarian cancer, breast cancer an …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆